fashion -WSS

fashion

author：fashion 2025-08-10 00:15:57 - browse：73

Treeline Northwest — AP Photo/Ted S. Warren

Josh Bilenker’s last company, Loxo Oncology, was purchased by Eli Lilly for $8 billion. No surprise, then, that his next effort has already raised at least $473 million in funding from private investors even before telling the public what, exactly, it is working on.

Treeline Biosciences, the new venture by Bilenker and Jeffrey Engelman, formerly Novartis’s top cancer researcher, has hired more than 130 people across three research sites in little more than a year, according to a company blog post, regulatory filings, and STAT reporting.

Treeline’s website doesn’t mention a single drug target or disease. In a paper published last year in Nature Cancer, Engelman and several colleagues reviewed the history of a class of cancer drugs called PI3 kinase inhibitors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Insmed lung disease drug hits target in key Phase 3 trial

focus

WSS

Report: NIH

Addiction doctors spar with methadone clinics over legislation

Startling documents reveal new facets of Sacklers' opioid empire

AI used to predict Covid

First Opinion Podcast: What happens when kids become caregivers?

NIH documents show early flaws of $1.6 billion long Covid program

explore

fashion

explore

Medicare details structure of new drug price negotiation program

Intellia reports positive results for its CRISPR

Moonlake's readout produced a cash windfall. Risks remain

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

BioMarin wins approval for gene therapy to treat hemophilia A

Addiction doctors spar with methadone clinics over legislation

As demand for Covid shots wanes, Moderna seeks its next success

David Sabatini, ex

Tori Bowie and the unacceptable rates of Black maternal death

Dark money group runs ads on China biotech bill

leisure time

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Prosthetic arm enables patients to feel the objects they grip

Ionis drug prevents swelling attacks due to hereditary angioedema

Kaiser's Risant Health gobbled up Geisinger. Who is next?

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Wikipedia

entertainment

focus

hotspot